瑞舒伐他汀对缺血性脑血管病患者颈动脉硬化斑块及超敏C―反应蛋白影响.docVIP

瑞舒伐他汀对缺血性脑血管病患者颈动脉硬化斑块及超敏C―反应蛋白影响 　　【摘要】 目的 观察瑞舒伐他汀对缺血性脑血管病患者颈动脉硬化的疗效。方法 伴有颈动脉粥样硬化及血脂异常的缺血性脑血管病患者90例随机分为两组， 常规组42例， 给予常规药物治疗， 瑞舒伐他汀组48例， 在常规治疗基础上加瑞舒伐他汀治疗， 疗程12周；比较两组治疗前后血清超敏C-反应蛋白（hs-CRP）、颈动脉内-中膜厚度（IMT）、颈动脉斑块数量及血脂的变化。结果 常规组前后颈hs-CRP、动脉IMT、斑块数量以及血脂水平差异无统计学意义（P0.05）；瑞舒伐他汀组治疗后hs-CRP、颈动脉IMT、斑块数量以及血脂水平显著降低（P0.05）；与常规组治疗后比较， 差异有统计学意义（P0.05）。结论 瑞舒伐他汀能显著降低缺血性脑血管病患者hs-CRP水平， 延缓和逆转颈动脉粥样硬化， 并可能预防脑血管病复发。 　　【关键词】 瑞舒伐他汀；颈动脉硬化；C-反应蛋白 　　【Abstract】 Objective To observe the curative effect of rosuvastatin in the treatment of carotid artery atherosclerosis （CAA） of patients with ischemic cerebrovascular disease. Methods A total of 90 cases of ischemic cerebrovascular disease with CAA and dyslipidemia were randomly divided into two groups. Conventional group （n=42） received the conventional drug treatment for 12 weeks， and rosuvastatin group （n=48） received the rosuvastatin treatment in addition for 12 weeks. The changes of serum high sensitive C reactive protein （hs-CRP）， carotid artery intima-media thickness （IMT）， number of carotid plaques and the blood lipids before and after treatment were compared between the 2 groups. Results The changes of carotid artery IMT， number of carotid plaques and blood lipids had no significant difference in conventional group. The levels of hs-CRP， carotid artery IMT， number of carotid plaques and blood lipids were significantly decreased in the rosuvastatin group after treatment （P0.05）. Compared with the conventional group after treatment， the differences were statistically significant （P0.05）. Conclusion Rosuvastatin can effectively reduce the level of hs-CRP， while suspending and reversing the progression of CAA in patients with ischemic cerebrovascular diease. It may prevent the recurrence of cerebrovascular disease. 　　【Key words】 Rosuvastatin； Carotid artery atherosclerosis； C-reactive protein 　　颈动脉粥样硬化是导致脑血管疾病（CVD）的重要因素之一[1]， 动脉硬化程度越严重， 引发脑血管疾病的可能性越大。瑞舒伐他汀具有降脂、逆转和稳定动脉粥样硬化斑块的作用。本研究拟通过观察瑞舒伐他汀对颈动脉硬化斑块及超敏C-反应蛋白（hs-CRP）的影响， 为颈动脉硬化患者的治疗与预防提供依据。